Medibank stock rating upgraded by Morgan Stanley on health expansion

Morgan Stanley upgraded Medibank Pvt Ltd. (ASX:MPL) to Overweight from Equalweight, raising its price target to AUD5.57 from AUD4.50. The upgrade is driven by Medibank's strong health insurance franchise, consistent margins, and strategic transformation into a broader health company, aligning with the longevity theme. Despite Medibank's 34% year-to-date share price increase, Morgan Stanley views its approximately 21.5x next-twelve-months P/E multiple as "undemanding," forecasting 6-7% EPS growth through FY27, with the new price target representing the highest among covering analysts.

Analysis

Morgan Stanley has upgraded Medibank Pvt Ltd. (ASX:MPL) to Overweight from Equalweight, issuing a new price target of AUD5.57, which is now the highest among covering analysts. The upgrade is predicated on Medibank's robust health insurance franchise, which demonstrates consistent margins, and its strategic transformation into a diversified health company through investments in primary and specialist care. This pivot positions the company to capitalize on the long-term longevity theme. Despite a significant 34% year-to-date share price appreciation, far outpacing the ASX200's 4% gain, Morgan Stanley views the valuation as attractive. The firm notes that Medibank's next-twelve-months price-to-earnings multiple of approximately 21.5x is "undemanding" relative to both its historical valuation and comparable high-quality financial stocks. This valuation is supported by a steady earnings per share growth forecast of 6-7% for fiscal years 2025 through 2027.

Key Decisions for Investors

• Investors should consider the Morgan Stanley upgrade as a significant bullish signal, supported by a clear rationale of a strong core business and a compelling long-term growth strategy.
• Despite the stock's 34% year-to-date rally, the forward P/E multiple of 21.5x, described as undemanding, suggests potential for further appreciation if the forecasted 6-7% EPS growth is achieved.
• Long-term investors should evaluate Medibank's strategic shift into a broader healthcare provider, as its success in this area is a key lever for sustaining performance and justifying a premium valuation.